Drugs / MTX
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02799472 Background | Jun 2016 → Oct 2017 | rheumatoid arthritis | GlaxoSmithKline | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02799472 ↗ |
| Route | Oral | “administered orally or as SC injection” NCT02799472 ↗ |
| Route | Subcutaneous | “administered orally or as SC injection” NCT02799472 ↗ |